"The NHS Pathways trial, led by researchers from King's College London, was commissioned in the wake of the controversial Cass Report and the government's ban on puberty blockers for trans youth. The £10 million ($13.1 million) trial will study the effectiveness of the drugs by focusing on the physical, social and emotional wellbeing of 220 youngsters over a two-year period."
"Puberty blockers are a type of medication given to young trans people to prevent or delay unwanted changes brought on by puberty, such as hair growth, breast development or voice changes. The medication is physically reversible and has been used in the UK for around 35 years. Following the publication of information about the trial, legal letters have now been sent to medical regulators responsible for the trial, health secretary Wes Streeting, and NHS England"
Gender-critical campaigners threaten legal action against the UK government over the NHS Pathways puberty blockers trial, arguing it will harm participating children. The trial, led by King's College London researchers, follows the Cass review and the government's ban on puberty blockers for trans youth. The £10 million study will evaluate effects on physical, social and emotional wellbeing of 220 young people over two years and be the only NHS route to blockers under the ban. Puberty blockers are reversible and have been used in the UK for 35 years. Legal letters were sent by Bayswater Support Group supporters to regulators, the health secretary and NHS England.
Read at PinkNews | Latest lesbian, gay, bi and trans news | LGBTQ+ news
Unable to calculate read time
Collection
[
|
...
]